Clinical Study
Coexistence of Myeloid and Lymphoid Neoplasms: A Single-Center Experience
Table 1
Patient characteristics and response to treatment.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
DOB: Date of birth, MBL: Monoclonal B-cell lymphocytosis, MF: Myelofibrosis, B-CLL: B chronic lymphocytic leukemia, MM: Multiple myeloma, LHCDD: Light and heavy chain deposistion disease RBC: Red blood cell, MDS/MPN RS-T: Myelodysplastic syndromes/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis, CAD: Coronary artery disease, AH: Arterial hypertension, BPH: Benign prostate hyperplasia, NSCLC: NonSmall cell lung carcinoma, CR: Complete response, PR: partial response, MZL: Marginal zone lymphoma, PBL: Plasmablastic lymphoma, VCD: Bortezomib, cyclophosphamide, dexamethasone, RCOP: Rituximab cyclophosphamide vincristine prednisolone CHOP: Cyclophosphamide, doxorubicin, vincristine, prednisolone, NA: Nonapplicable. |